These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37016431)

  • 1. NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization.
    Narang S; Evensen NA; Saliba J; Pierro J; Loh ML; Brown PA; Kolekar P; Mulder H; Shao Y; Easton J; Ma X; Tsirigos A; Carroll WL
    Genome Biol; 2023 Apr; 24(1):64. PubMed ID: 37016431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
    Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
    Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by
    Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupéré-Richér D; Roth JS; Jing D; Casellas Román HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD
    Cancer Discov; 2022 Jan; 12(1):186-203. PubMed ID: 34417224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
    Jaffe JD; Wang Y; Chan HM; Zhang J; Huether R; Kryukov GV; Bhang HE; Taylor JE; Hu M; Englund NP; Yan F; Wang Z; Robert McDonald E; Wei L; Ma J; Easton J; Yu Z; deBeaumount R; Gibaja V; Venkatesan K; Schlegel R; Sellers WR; Keen N; Liu J; Caponigro G; Barretina J; Cooke VG; Mullighan C; Carr SA; Downing JR; Garraway LA; Stegmeier F
    Nat Genet; 2013 Nov; 45(11):1386-91. PubMed ID: 24076604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
    Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
    Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal evolution of the 3D chromatin landscape in patients with relapsed pediatric B-cell acute lymphoblastic leukemia.
    Narang S; Ghebrechristos Y; Evensen NA; Murrell N; Jasinski S; Ostrow TH; Teachey DT; Raetz EA; Lionnet T; Witkowski M; Aifantis I; Tsirigos A; Carroll WL
    Nat Commun; 2024 Aug; 15(1):7425. PubMed ID: 39198446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains.
    Lhoumaud P; Badri S; Rodriguez-Hernaez J; Sakellaropoulos T; Sethia G; Kloetgen A; Cornwell M; Bhattacharyya S; Ay F; Bonneau R; Tsirigos A; Skok JA
    Nat Commun; 2019 Oct; 10(1):4843. PubMed ID: 31649247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin enhances osteoblastogenesis of senescent bone marrow stromal cells through NSD2-mediated chromatin remodelling.
    Xie Y; Han N; Li F; Wang L; Liu G; Hu M; Wang S; Wei X; Guo J; Jiang H; Wang J; Li X; Wang Y; Wang J; Bian X; Zhu Z; Zhang H; Liu C; Liu X; Liu Z
    Clin Transl Med; 2022 Feb; 12(2):e746. PubMed ID: 35220680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
    Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
    J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
    Sankaran SM; Wilkinson AW; Elias JE; Gozani O
    J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ISWI chromatin remodeling complexes recruit NSD2 and H3K36me2 in pericentromeric heterochromatin.
    Goto N; Suke K; Yonezawa N; Nishihara H; Handa T; Sato Y; Kujirai T; Kurumizaka H; Yamagata K; Kimura H
    J Cell Biol; 2024 Aug; 223(8):. PubMed ID: 38709169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
    Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
    Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
    Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
    Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of LLC0424 as a Potent and Selective
    Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer.
    Kanaoka S; Okabe A; Kanesaka M; Rahmutulla B; Fukuyo M; Seki M; Hoshii T; Sato H; Imamura Y; Sakamoto S; Ichikawa T; Kaneda A
    Cancer Lett; 2024 Apr; 588():216815. PubMed ID: 38490329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
    He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
    Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance.
    Saint Fleur-Lominy S; Evensen NA; Bhatla T; Sethia G; Narang S; Choi JH; Ma X; Yang JJ; Kelly S; Raetz E; Harvey RC; Willman C; Loh ML; Hunger SP; Brown PA; Getz KM; Meydan C; Mason CE; Tsirigos A; Carroll WL
    Cancer Res; 2020 Dec; 80(23):5189-5202. PubMed ID: 33067268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NSD2-mediated H3K36me2 exacerbates osteoporosis via activation of hoxa2 in bone marrow mesenchymal stem cells.
    He G; Ke Y; Yuan J; Zhang B; Dai L; Liu J; Zhang X
    Cell Signal; 2024 Sep; 121():111294. PubMed ID: 38996954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convergent epigenetic evolution drives relapse in acute myeloid leukemia.
    Nuno K; Azizi A; Koehnke T; Lareau C; Ediriwickrema A; Corces MR; Satpathy AT; Majeti R
    Elife; 2024 Apr; 13():. PubMed ID: 38647535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.
    Hanley RP; Nie DY; Tabor JR; Li F; Sobh A; Xu C; Barker NK; Dilworth D; Hajian T; Gibson E; Szewczyk MM; Brown PJ; Barsyte-Lovejoy D; Herring LE; Wang GG; Licht JD; Vedadi M; Arrowsmith CH; James LI
    J Am Chem Soc; 2023 Apr; 145(14):8176-8188. PubMed ID: 36976643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.